Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Finished Goods (2025)

Soleno Therapeutics (SLNO) has disclosed Finished Goods for 1 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Finished Goods changed N/A to $6.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.0 million, a N/A change, with the full-year FY2025 number at $6.0 million, changed N/A from a year prior.
  • Finished Goods was $6.0 million for Q4 2025 at Soleno Therapeutics, up from $525000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $6.0 million in Q4 2025 to a low of $262000.0 in Q2 2025.